Sign in
ENOB Stock Price, Chart, Stats & News
Enochian Biosciences, Inc.
Save
45.38M
Market cap
–
Current P/E
–
Forward P/E
ENOB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.00% |
ROA | -1882.92% |
ROE | -1241.35% |
D/E | -0.20x |
Interest coverage ratio | 362.36x |
ENOB valuation
P/E | – |
P/S | – |
P/B | -1.23x |
P/CF | -2.93x |
P/FCF | 0.00x |
P/OCF | -2.93x |
PEG | 0.02x |
EV multiple | -0.36x |
About
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase.
Similar securities
Based on sector and market capitalization
Report issue